What is Generate Biomedicines, Inc. 's investing cash flow?

Generate Biomedicines, Inc. (GENB) reported investing cash flow of -$259.93M in Q1 2026.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Generate Biomedicines, Inc. GENB Investing Cash Flow

Investing Cash Flow at other companies

MYR GroupMYRG

-$15.18M-39.4%

SSR MiningSSRM

-$86.27M+43.2%

NNN REITNNN

-$106.36M+50.6%

Piper SandlerPIPR

-$3.31M+70.3%

RepligenRGEN

-$3.99M+94.6%

LKQLKQ

-$42M+16.0%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's investing cash flow?: Generate Biomedicines, Inc. (GENB) reported investing cash flow of -$259.93M in Q1 2026.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.